SCHEMBL9956780

SCHEMBL9956780

O=CC1c2ccccc2-c2c(C(=O)O)cccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
HNF4A P41235 1/20 0.46
MYC P01106 1/20 0.45
GAA P10253 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
GFER P55789 1/20 0.43
KMT2A Q03164 1/20 0.43
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 5/20 0.40
POLB P06746 3/20 0.40
CYP2C9 P11712 3/20 0.39
CYP1A2 P05177 1/20 0.39
NR4A1 P22736 1/20 0.38
NR4A2 P43354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27755760 0.79 MAOA (0.47) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL28328327 0.77 MAOA (0.42) ALDH1A1MAPTLMNAL3MBTL1HNF4A
SCHEMBL3552317 0.76 ALDH1A1 (0.51) ALDH1A1MAPTLMNAL3MBTL1HNF4A
SCHEMBL3552315 0.76 ALDH1A1 (0.51) ALDH1A1MAPTLMNAL3MBTL1HNF4A
SCHEMBL3552319 0.76 ALDH1A1 (0.51) ALDH1A1MAPTLMNAL3MBTL1HNF4A
SCHEMBL31670439 0.76 ALDH1A1 (0.51) ALDH1A1MAPTLMNAL3MBTL1HNF4A
SCHEMBL27736817 0.76
SCHEMBL27715968 0.76 CA1 (0.36) ALDH1A1MAPTLMNAL3MBTL1GAA
SCHEMBL224931 0.75 GPR3 (0.41) ALDH1A1LMNAMEN1KMT2APOLB
SCHEMBL27818816 0.73 GPR3 (0.39) ALDH1A1MEN1KMT2APOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11406618-B2 Polymer-des-ethyl sunitinib conjugates NEKTAR THERAPEUTICS (US) 2022-08-09 US disclosed
US-20190142798-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS 2019-05-16 US disclosed
US-20190142798-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS 2019-05-16 US disclosed
US-10220020-B2 Polymer-des-ethyl sunitinib conjugates NEKTAR THERAPEUTICS (US) 2019-03-05 US disclosed
US-10220020-B2 Polymer-des-ethyl sunitinib conjugates NEKTAR THERAPEUTICS (US) 2019-03-05 US disclosed
EP-2654797-B1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2017-11-08 EP disclosed
EP-2654797-B1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2017-11-08 EP disclosed
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-06 US disclosed
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-06 US disclosed
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-06 US disclosed
EP-2654797-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES Nektar Therapeutics (US) 2013-10-30 EP disclosed
WO-2012088522-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES NEKTAR THERAPEUTICS (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10220020-B2 Polymer-des-ethyl sunitinib conjugates KDR, FLT4, FLT1 ALDH1A1 3041/4885MAPT 918/4885LMNA 3034/4885
US-11406618-B2 Polymer-des-ethyl sunitinib conjugates KDR, FLT4, FLT1 ALDH1A1 3041/4885MAPT 918/4885LMNA 3034/4885
US-20140039030-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES KDR, FLT4, FLT1 ALDH1A1 3041/4885MAPT 918/4885LMNA 3034/4885
US-20190142798-A1 POLYMER-DES-ETHYL SUNITINIB CONJUGATES KDR, FLT4, FLT1 ALDH1A1 3041/4885MAPT 918/4885LMNA 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.